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. However, it should be recognized that while COX-2 is inducible, its products are not always proinflammatory. Constitutive COX-2 in the vasculature generates mainly prostacyclin, which is a vasodilator and inhibitor of platelet aggregation. Therefore, inhibition of COX-2 may alter the balance of prothrombotic (versus antithrombotic) eicosanoids and predispose susceptible individuals to CV side effects (Justice and Carruthers, 2005; Davies and Jamali, 2004; Meagher, 2003; Mukherjee et al., 2002) .
A complex picture is emerging and the clinical safety (both GI and CV) of COX inhibitors most likely depends on a fine balance of factors. These factors include COX-1 and COX-2 inhibitory potency, the IC 50(COX) ratio (COX-2 versus COX-1), C b /IC 50(COX) ratios, PK, PD, PK-PD (dose response) for each COX form, tissue distribution of the inhibitor (relative to tissue distribution of each COX enzyme form) and therapeutic index (Lees et al., 2004; Meagher et al., 2003; Riendeau et al., 2001; Davies and Jamali, 2004; Justice and Carruthers, 2005) . The situation is complicated further by the presence of allelic variant forms of COX-1 and COX-2, which may impact not only efficacy, but predispose individuals to different levels of risk (Halushka et al., 2003; Cipollone et al., 2004) .
Factors governing systemic clearance (PK) have received particular attention. This is because the majority of marketed COX inhibitors are well absorbed, metabolized extensively, subject to relatively minimal first pass extraction, and exhibit linear PK ([S]/K m ≤0.1). Consequently, exposure and C b /IC 50(COX) ratios will depend on systemic clearance. In turn, systemic clearance will be governed by alterations in CL because it has been known for some time that the enzyme plays a role in the metabolism of many NSAIDs in vitro, and is thus considered a major determinant of CL tot int (Rodrigues and Rushmore, 2002; Miners and Birkett, 1998; Leeman et al., 1993; Zhao et al., 1992) . The catalytic efficiency (k cat /K m ratio) of the allelic variant forms of the enzyme (e.g., CYP2C9*2 and CYP2C9*3) is reduced as a result of a single amino acid substitution (Takanashi et al., 2000; Tang et al., 2001; Miners and Birkett, 1998; Rodrigues and Rushmore, 2002) . Therefore, due to the high incidence of CYP2C9-related polymorphisms in some populations (e.g., frequency of CYP2C9*1/*3 genotype is 12% in white subjects), one can hypothesize that the occurrence of side effects is increased in numerous subjects genotyped heterozygous, or homozygous, for the CYP2C9*2 or CYP2C9*3 alleles (Kirchheiner and Brockmoller, 2005; Schwarz, 2003; Lee, 2004; Xie et al., 2002; Rettie and Jones, 2005) . However, the picture is not so simple and the data so far are not clear.
For example, Wynne et al (1998) hypothesized that PK might explain the risk of major GI haemorrhage with NSAIDs, with bleeders exhibiting a reduced clearance of NSAIDs compared with non-bleeders. A number of patients (n = 50), hospitalized with GI bleeds while taking piroxicam, indomethacin, diclofenac, or naproxen, were evaluated. There were no significant differences in peak plasma concentration, time-topeak plasma concentration, or AUC po between bleeders and controls for any of the NSAIDs studied. The authors concluded that their results failed to support the hypothesis.
In a separate study, Martin et al (2001) evaluated the effect of CYP2C9 genotype on the incidence of gastric ulceration in a relatively small number of subjects (n = 23) receiving indomethacin, diclofenac, naproxen, ibuprofen, piroxicam or sulindac. Although some of This article has not been copyedited and formatted. The final version may differ from this version. the subjects were genotyped CYP2C9*1/*2 (17%) and CYP2C9*1/*3 (13%), the incidence of ulceration was not associated with genotype.
More recently, Martinez et al (2004) were able to assess CYP2C9 genotyped subjects receiving NSAIDs that underwent "extensive" CYP2C9-dependent metabolism (e.g., celecoxib, diclofenac, ibuprofen, indomethacin, lornoxicam, piroxicam, or naproxen) and other drugs that were not considered CYP2C9 substrates (e.g., salicylates
and acetaminophen). The authors conclude that the association of variant CYP2C9 alleles and the risk of acute GI bleeding shows a gene-dose effect, and that it is higher in patients receiving drugs that are metabolized mainly by CYP2C9 (odds ratio of 2.6 when compared to non-bleeding subjects). It is concluded also that CYP2C9 genotyping may identify a subgroup of individuals who are at a potentially increased risk of acute GI bleeding. Interestingly, the observed risk was related largely to the CYP2C9*2 allele, which is unexpected because decreases in the k cat /K m ratio in vitro are more pronounced with recombinant CYP2C9*3 (Rodrigues and Rushmore, 2002) . Therefore, the authors hypothesized that the association of CYP2C9*2 with NSAID-related GI bleeding risk may be related to a combined effect of mutations on CYP2C8 (CYP2C8*3 allele) and CYP2C9 (CYP2C9*2 allele), and the work of Yasar et al (2002) was cited. This raises an interesting possibility that for substrates metabolized by both CYP2C8 and CYP2C9, an impaired clearance in vivo previously attributed to the CYP2C9*2 variant could in part be related to CYP2C8*3. But how many COX inhibitors are metabolized by CYP2C9 and CYP2C8 (Totah and Rettie, 2005) ?
The reports of Wynne et al (1998 ), Martin et al (2001 ), and Martinez et al (2004 focused on the GI side effects associated with COX inhibitors. In all three cases, This article has not been copyedited and formatted. The final version may differ from this version. however, no effort was made to evaluate CYP2C9 genotype in relation to changes in PK and COX inhibition. More importantly, existing P450 reaction phenotype and clinical ADME data for the drugs in each study were not considered.
Kinetic considerations
Before considering the role of CYP2C9, it is important to note that many pathways may contribute to the overall clearance of a drug. For example, an absorbed drug may be cleared unchanged via hepatic (biliary) and renal routes. As a result, not all of the dose is eliminated via hepatic metabolism (f h •f m ≠ 1). Even if a drug is metabolized extensively, it is possible that multiple enzyme systems are involved and the overall clearance is governed by a combination of P450 and non-P450 (e.g., UGT, FMO, (Rodrigues and Rushmore, 2002) .
For the sake of discussion, the theoretical relationship (Equation 1) between the product f m • f m,CYP (specifically, f m • f m,CYP2C9(EM) ) and the AUC po difference in PM (AUC po(PM) ) versus EM (AUC po(EM) ) subjects is shown below (Rodrigues and Rushmore, 2002) . A similar relationship is commonly used to evaluate the effect of an inhibitor on the AUC of a substrate. In this instance, however, one is comparing the AUC ratio across subjects of different phenotypes, or genotypes, and it is assumed that the dose, the fraction of the dose absorbed, and the unbound fraction in blood is the same in both EM and PM subjects. In addition, it is assumed that gut first pass is negligible, that the drug This article has not been copyedited and formatted. The final version may differ from this version. has to accept also that hepatic extraction is blood flow-limited (e.g., well-stirred model).
It is worth noting that recombinant CYP2C9*1 and CYP2C9*3 have been shown to exhibit non-hyperbolic (non-Michaelis Menten) single-K m kinetics with substrates such as naproxen (e.g., biphasic) and piroxicam (e.g., substrate inhibition) (Tracy et al., 2002) .
The impact of such non-hyperbolic kinetics in vivo is not known. However, if product formation (parent elimination) is first order, then concerns about kinetic behavior at higher substrate concentrations (≥K m ) are minimized.
Equation 1:
Estimates of f m,CYP2C9(EM) are based on in vitro P450 reaction phenotyping data, which encompasses inhibition studies with CYP2C9-selective inhibitors like sulfaphenazole or anti-CYP2C9 antibodies. Kinetic studies can be conducted also with human liver microsomes (genotyped tissue) and recombinant P450 proteins (Rodrigues and Rushmore, 2002) . At the same time, one can attempt to use clinical ADME data (e.g., fraction of dose recovered in excreta as oxidative metabolites) to generate estimates of f m . Again one assumes that the drug is eliminated by the liver only and that non-P450
This article has not been copyedited and formatted. The final version may differ from this version. formed, the sulfide undergoes extensive oxidation back to parent (Hamman et al., 2000; Gibson et al., 1987; Hucker et al., 1973) . Formation of the sulfide is catalyzed by AO and does not involve P450 (Kitamura et al., 2001) . Similarly, oxidation of the sulfide to the (R)-sulfoxide is not catalyzed by P450 and is FMO-dependent in human liver and kidney microsomes (Hamman et al., 2000) . Although catalyzed by recombinant human FMOs, the enzymes responsible for (S)-sulfoxide formation in tissue microsomes have not been identified (Hamman et al., 2000) . However, P450 form-selective inhibitors like sulfaphenazole (CYP2C9 selective) have a minimal impact on (R)-and (S)-sulfoxide formation in human liver microsomes (Hamman et al., 2000) . Therefore, existing data indicate that COX inhibition will be governed by exposure to the sulfide form and the balance of pathways leading to its formation and clearance. CYP2C9 plays a minimal role in both pathways (Table 1) .
Ketoprofen. At the time of writing, it was not possible to locate any published reports describing the CYP2C9-dependent metabolism of ketoprofen in vitro. However, a number of reports were found that described the clinical ADME profile of the drug. In all cases, it was evident that direct glucuronidation was the major clearance pathway. For example, Jamali and Brocks (1990 ), Foster et al (1988 ), and Ishizaki et al (1980 reported that as much as 80% of the dose in man was recovered as the acyl glucuronide.
Therefore, f m • f m,CYP2C9(EM) is low (≤ 0.2) even if the majority of the oxidative metabolism were to be catalyzed by CYP2C9 (Table 1) .
Naproxen. Like ketoprofen, a large fraction of a naproxen dose (60%) is recovered as the products of direct glucuronidation (Vree et al., 1993a (Vree et al., , 1993b P450s such as CYP2C8 and CYP1A2 are involved also (Rodrigues et al., 1996; Miners et al., 1996; Tracy et al., 1997) . Therefore, CYP2C9 plays a relatively minor role in the overall clearance of naproxen also ( Table 1) .
Diclofenac. For naproxen, ketoprofen, and sulindac, there are no reports describing the effect of CYP2C9 genotype on PK and inhibition of COX activity. The same cannot be said for diclofenac, which was also included in the studies described by Martin et al (2001) and Martinez et al (2004) . In fact, a number of labs have reported that the PK of diclofenac is not related to CYP2C9 genotype, despite extensive (f m,CYP2C9(EM) ~0.8)
CYP2C9-dependent 4'-hydroxylation in human liver microsomes (Rodrigues and Rushmore, 2002; Brenner et al., 2003; Kirchheiner et al., 2003a) . Therefore, one can conclude that CYP2C9 plays a minor role in the overall clearance of diclofenac ( Table 1) . Kirchheiner et al (2003a) showed also that CYP2C9
genotype has a minimal impact on the inhibition of COX-1 and COX-2 activity in subjects receiving diclofenac. Therefore, a number of groups have questioned the utility of diclofenac as a phenotyping agent (Rodrigues and Rushmore, 2002) .
Although human ADME data with genotyped subjects are lacking, Kumar et al for 4'-hydroxy diclofenac. This estimate is based on the urinary recovery of total 4'-hydroxy diclofenac (conjugated and unconjugated) and is supposedly reflective of CYP2C9 phenotype. Ultimately, the impact of CYP2C8 on the disposition of diclofenac and its metabolites will require clinical studies with suitably genotyped subjects.
Indomethacin. In the presence of human liver microsomes, indomethacin O-
demethylation is monophasic (single K m ) and is catalyzed largely by CYP2C9
(f m,CYP2C9(EM) ~0.9) (Nakajima et al., 1998). However, like naproxen, indomethacin can undergo direct glucuronidation and human ADME data indicate that 22% of the dose is recovered as the acyl glucuronide (Duggan et al., 1972 ). An additional 11% and 13% of the dose is recovered as unchanged parent drug and N-deschlorobenzoylindomethacin.
The latter is thought to be formed by carboxylesterase not P450 (Nakajima et al., 1998).
Therefore, it can be estimated that about 50% of the dose (f m ~ 0.5) is cleared via P450-dependent metabolism (O-demethylation) and that f m •f m,CYP2C9(EM) is ~0.5 (Table 1) .
Although there are no published reports of indomethacin pharmacokinetics in genotyped subjects, AUC po(PM) /AUC po(EM) ratios of 1.8 (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) are anticipated. It is not known is such increases in AUC po will impact the COX-1 and COX-2 inhibition profile of the drug. almost exclusively (f m,CYP2C9(EM) > 0.9) by CYP2C9 (Tracy et al., 1995 (Tracy et al., , 1996 Yamazaki et al., 1998) . The metabolism and disposition of flurbiprofen has been evaluated in man using radiolabeled and non-radiolabeled drug (Szpunar et al., 1987; Risdall et al., 1978) . (Table 1) . If true, AUC po(PM) /AUC po(EM) ratios of 3.0 (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) would be expected. To date, this has not been confirmed clinically and only PK data with heterozygotes (CYP2C9*1/*2 and CYP2C9*1/*3) have been reported (Lee et al., 2003) .
In this instance, a statistically significant increase in AUC po was observed only with CYP2C9*1/*3 subjects (mean AUC po(PM) /AUC po(EM) ratio = 1.7). Assuming a gene dose effect, AUC po(PM) /AUC po(EM) ratios of greater than 1.7 are possible in CYP2C9*3/*3 subjects. The impact of CYP2C9 genotype on COX-1 and COX-2 inhibition has not been reported.
This article has not been copyedited and formatted. The final version may differ from this version. When incubated with NADPH-fortified human liver microsomes, the oxidative metabolism of racemic ibuprofen is inhibited significantly by sulfaphenazole (87%), which suggests a major role for CYP2C9 (Leemann et al., 1993) . This has been recombinant proteins (CYP2C9 and CYP2C8 variants), and a larger number of individual genotyped (CYP2C9 and CYP2C8) human livers. This is important because the ratio of CYP2C9-to-CYP2C8 can vary considerably (1.4 to >300) in different livers (Lasker et al., 1998; Lapple et al., 2003) .
Human ADME data indicate that the (S)-(+)-enantiomer undergoes no detectable chiral inversion and is cleared via glucuronidation (14% of the dose), 2-hydroxylation (28% of the dose) and carboxy metabolite formation (45% of the dose) (Davies 1998; Rudy et al., 1991) . As a result, f m is high (~0.7) and CYP2C9 genotype is expected to impact the PK of (S)-(+)-ibuprofen (f m •f m,CYP2C9(EM) ~0.5; AUC po(PM) /AUC po(EM) ratios of 1.8 for CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) ( Table 1 ). In agreement,
Kirchheiner et al (2002) have shown that the AUC of (S)-(+)-ibuprofen is increased (1.7-fold) in CYP2C9*3/*3 subjects (CYP2C8 genotype not reported) and that the PD relationship describing the inhibition of COX-2 (prostaglandin E 2 formation ex vivo) and COX-1 (thromboxane B 2 formation ex vivo) is altered. It is not know if these alterations in PK-PD make CYP2C9*3/*3 subjects more susceptible to adverse side effects. More recently, even greater increases (3.0-fold) in (S)-(+)-ibuprofen AUC have been reported for CYP2C9*3/*3 (CYP2C8*1/*1) subjects (Garcia-Martin et al., 2004) . In the same study, the AUC of (S)-(+)-ibuprofen was increased as much as 7.7-fold in subjects genotyped CYP2C9*3/*3 (CYP2C8*1/*3) or CYP2C9*2/*2 (CYP2C8*3/*3). These results suggest that CYP2C8-dependent metabolism of (S)-(+)-ibuprofen in vitro may be under-estimated and that the fraction of (S)-(+)-ibuprofen clearance via CYP2C8 and
CYP2C9 is considerable (>0.8). Such large increases in (S)-(+)-ibuprofen AUC will
This article has not been copyedited and formatted. The final version may differ from this version. In agreement with in vitro data, the pathway giving rise to 5'-carboxy meloxicam has been identified as major and accounts for about 70% (f m ~0.7) of the radiolabeled dose (Schmid et al., 1995) . An additional 10% and ~6% of the dose is recovered as parent and ring opened metabolite, respectively. Therefore, f m •f m,CYP2C9(EM) is estimated to be 0.4 to 0.6 and AUC po(PM) /AUC po(EM) ratios of 1.6 to 2.2 (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) are anticipated (Table 1 ). To date, there are no reports describing the effect of CYP2C9 genotype on the PK of meloxicam.
Lornoxicam. Bonnabry et al (1996) and Iida et al (2004) (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) is anticipated (Table 1) . Recently, it was reported that the AUC po of lornoxicam is increased 1.9-fold in heterozygous (CYP2C9*1/*3 or CYP2C9*1/*2) subjects . No CYP2C9*3/*3 subjects were included in the same study. However, it is reasonable to expect that AUC po increases will be greater in CYP2C9*3/*3 subjects.
Tenoxicam.
Tenoxicam is metabolized extensively (>95%) and about two thirds of the dose is recovered in the urine. The remainder of the dose is eliminated via the bile (Gonzalez and Todd 1987; Nilsen 1994; Dell et al., 1984) . 5'-hydroxy tenoxicam (~40% of the dose) and 6-oxy tenoxicam (~30% of the dose) are considered major metabolites This article has not been copyedited and formatted. The final version may differ from this version. 
Piroxicam. Like tenoxicam, piroxicam is metabolized extensively and only a minor
fraction of the dose (≤10%) is recovered unchanged (Olkkola et al., 1994; Woolf and Radulovic, 1989; Richardson et al., 1987; Brogden et al., 1984) . Although various metabolites have been identified in human excreta, 5'-hydroxy piroxicam is the major metabolite and accounts for about 60% of the dose (f m ~0.6) (Wiseman and Boyle, 1980; Richardson et al., 1987) . When incubated with human liver microsomes, 5'-hydroxylation of piroxicam is inhibited by sulfaphenazole (≥90%) and so CYP2C9 plays a major role in the reaction (f m,CYP2C9(EM) ≥0.9) (Leemann et al., 1993) . In addition, the is estimated to be ≥0.54 and an AUC po(PM) /AUC po(EM) ratio ≥1.8 (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) is anticipated (Table 1 ). In agreement, piroxicam AUC po is increased 1.6-and 3.7-fold in CYP2C9*1/*3 and CYP2C9*3/*3 subjects, respectively.
This article has not been copyedited and formatted. The final version may differ from this version. was marketed at the 10-and 20-mg dose level, and studies showed good tolerability at 40-mg. Thus it appears that AUC po increases of less than 2-fold do not require dose adjustment (Chavez and Dekorte, 2003) . To date, the impact of CYP2C9 genotype on valdecoxib PK has not been reported.
COX-2 selective inhibitors (COX-2/COX-1 IC
Celecoxib. There are numerous reports describing the metabolism of celecoxib in vitro.
Data indicate that methyl hydroxylation is a major pathway in human liver microsomes, and that the reaction is catalyzed largely (70% to 90%) by CYP2C9 (f m,CYP2C9(EM) ≥ 0.7)
with CYP3A4 playing less of a role (≤25%) (Tang et al., 2000; Sandberg et al., 2002 ).
The results of additional studies show that the contribution of CYP2C9 (versus CYP3A4) in a bank of human liver microsomes is greatly dependent on the CYP3A4-to-CYP2C9 content ratio (Tang et al., 2001 ). The contribution of CYP2C9 is greater (f m,CYP2C9(EM) ~0.8) in livers where CYP3A4 levels are lower. When the CYP3A4-to-CYP2C9 content ratio is high (~8.0), the contribution of CYP3A4 increases to 40% (f m,CYP2C9(EM) ~0.6).
There are two reports describing the metabolism of celecoxib after incubation with human liver microsomes of genotyped subjects and preparations of recombinant CYP2C9 (Tang et al., 2001; Sandberg et al., 2002) . In both cases, it was shown that the reduction in catalytic efficiency was greater for recombinant CYP2C9*3 (≥70%) than CYP2C9*2 (≤35%). The report of Sandberg et al., (2002) included livers from a larger set of organ donors and it was demonstrated that the rate of celecoxib hydroxylation was decreased (~50%) in livers genotyped CYP2C9*1/*3 (versus CYP2C9*1/*1). In contrast, celecoxib hydroxylation was impacted minimally in livers genotyped CYP2C9*1/*2.
The same study also included one liver genotyped CYP2C9*3/*3 (~80% decrease in activity) and four livers genotyped CYP2C9*2/*2 (36% decrease in activity).
This article has not been copyedited and formatted. The final version may differ from this version. Once formed, methyl hydroxy celecoxib is oxidized further to the corresponding carboxylic acid metabolite via cytosolic alcohol dehydrogenase. Therefore, the metabolic profile of celecoxib is relatively simple (Sandberg et al., 2002) . This is borne out in human subjects receiving a single oral dose of [ 14 C]celecoxib, where the overall recovery of the dose is good (~95%) (Paulson et al., 2000) . In such subjects, up to 86% of the dose is recovered as methyl hydroxy celecoxib and carboxy celecoxib (f m ~0.9).
CYP2C9, therefore, is predicted to play a major role in the overall clearance of celecoxib (f m • f m,CYP2C9(EM) = 0.5-0.8) and AUC po(PM) /AUC po(EM) ratios of 1.8 to 3.6 (CYP2C9*3/*3 versus CYP2C9*1/*1 subjects) are anticipated (Table 1) .
At the time of writing, three reports described the PK of celecoxib in adult (CYP2C9 genotyped) subjects. Two reported PK for a single dose of celecoxib (Kirchheiner et al., 2003b; Tang et al., 2001 ), while the third described steady state PK parameters following twice daily doses of celecoxib (200-mg) for 15 days (Brenner et al., 2003) . It is clear from all three reports that CYP2C9*1/*2 genotype has a minimal impact on celecoxib PK. In agreement with Brenner et al (2003) , Kirchheiner et al (2003b) showed that the AUC po of celecoxib in CYP2C9*2/*2 subjects is not statistically different from those individuals genotyped CYP2C9*1/*1. In all three studies, the AUC po in CYP2C9*1/*3 subjects was ~2.0-fold higher (versus CYP2C9*1/*1 subjects). However, it is important to note that such an increased AUC po was observed in only two out of the four CYP2C9*1/*3 subjects included in the study conducted by Brenner et al (2003) .
Interestingly, one CYP2C9*3/*3 individual was included in the same study and no (n = 1 subject) and 3.3-fold (n = 3 subjects) higher AUC po in their respective CYP2C9*3/*3 subjects. The results of Brenner et al (2003) are also difficult to reconcile in light of the fact that the AUC po of single dose celecoxib is increased (~2.3-fold)
following fluconazole (Davies et al., 2000) . More recently, Stempak et al (2005) reported that the AUC po of a single celecoxib dose (250-mg/m 2 dose, equivalent to 400-mg) was ~10-fold higher in a pediatric patient genotyped CYP2C9*3/*3 (versus two CYP2C9*1/*1 patients). A similar result was obtained at a steady state following a bid regimen at the same dose level.
Although ketoconazole has no effect on the AUC po of celecoxib (Davies et al., 2000) , it is possible that higher CYP3A4 activity may have compensated and negated the impact of CYP2C9*3/*3 genotype in some of the individuals reported by Brenner et al (2003) . Alternatively, it is possible that, upon multiple dosing (e.g., 200 mg bid), celecoxib might behave as an auto-inducer of CYP3A4 and CYP2C9 in CYP2C9*3/*3 subjects (maximal plasma concentrations of total celecoxib at steady state are projected to be close to 15 µM in these subjects). At least in vitro, celecoxib (1 to 15 µM) has been shown to transactivate human pregnane-X-receptor and induce CYP3A4 in immortalized human hepatocytes (Fa2N-4 cells) (Michael Sinz, Bristol-Myers Squibb, personal communication). Therefore, induction of CYP3A4 in the gut and liver during celecoxib first pass is a possibility.
Additional studies are needed and it will be necessary to evaluate the effect of CYP2C9 genotype and CYP3A4 activity on celecoxib PK, and COX inhibition, following multiple doses of the drug. This is important because dose adjustment has been recommended for subjects receiving fluconazole and other CYP2C9 inhibitors Lumiracoxib. It has been reported that lumiracoxib is "extensively" metabolized by CYP2C9 in vitro, although the in vitro metabolic profile and P450 reaction phenotype have not been published (Mangold et al., 2004) . Despite metabolism by CYP2C9 in vitro, fluconazole has a relatively minimal effect on the PK of lumiracoxib (~1.2-fold increase in AUC po(EM) ) and its ability to inhibit COX-1. Although additional "compensatory" metabolic pathways have been proposed, such pathways are not apparent (Scott et al., 2004; Mangold et al., 2004) . For example, only a minor fraction of a [ 14 C]lumiracoxib dose (<10%) is recovered unchanged, or in the form of lumiracoxib acyl glucuronide. In fact, the majority of the dose in CYP2C9*1/*1 subjects is recovered as the products of oxidation on the 5-methyl group and dihaloaromatic ring (Mangold et al., 2004) . Despite the minimal effect of fluconazole, the impact of CYP2C9 genotype on lumiracoxib PK needs to be determined.
Conclusions
If it is assumed that the CV and GI side effects of COX inhibitors are related to systemic exposure, then factors governing their clearance will be considered important.
Because most COX inhibitors (NSAIDs) are metabolized by CYP2C9 in vitro, CYP2C9 genotype may be considered by some to be a clinically relevant risk factor. The variant forms of CYP2C9 (e.g., CYP2C9*3) are less catalytically efficient and one could hypothesize that systemic exposure, and the risk of side effects, is elevated in subjects This article has not been copyedited and formatted. The final version may differ from this version. (2001), and two of the seven "extensive" CYP2C9 substrates reported by Martinez et al (2004) . When it comes to CYP2C9 genotype, and its impact on PK, it is clear that not all COX inhibitors are the same.
Even when CYP2C9 involvement is major, one has to critically evaluate each COX inhibitor on an individual basis, and take into account the available data related to all clearance mechanisms (e.g., renal clearance, direct conjugation, non-P450 oxidation, and metabolism by other P450s). This is important for currently marketed COX inhibitors such as ibuprofen and celecoxib, where additional P450 forms have been implicated in clearance and literature reports appear contradictory (Kirchheiner et al., 2002; Garcia-Martin et al., 2004; Brenner et al., 2003; Kirchheiner et al., 2003b It is only with long-term study of such patients that one can assess critically the impact of CYP2C9 genotype on PK, PD, and the side effect profile.
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